FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata
Why now
Thesis: Incremental label win, modest relative to Lilly's GLP-1 scale
Catalyst to watch: Pediatric launch uptake and payer coverage decisions
Main risk: Alopecia areata is a small revenue pool for Lilly
Why it matters
Pediatric label expansion widens Olumiant's addressable market, adding incremental revenue for Lilly's immunology franchise.
Details
FDA approval supported by data from BRAVE-AA-PEDS, the first and largest Phase 3 study specifically designed to evaluate pediatric patients with severe alopecia areata (AA) Treatment with Olumiant resulted in substantial scalp hair regrowth, as well as improvements in eyebrows and...
Sources
- prnewswire · 2026-09-25 21:11 UTC